X

Trial Profile

An Open Label Non-randomized Phase II Study Exploring "Chemo-free " Treatment Association With Idelalisib + Obinutuzumab in Patient With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Aug 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Idelalisib (Primary) ; Obinutuzumab (Primary)
Indications Waldenstrom's macroglobulinaemia
Focus Therapeutic Use
Acronyms RemodelWM3

Most Recent Events

28 Aug 2023 Status changed from active, no longer recruiting to completed.
13 Jun 2023 This trial has been completed (End Date: 13 Apr 2023), according to European Clinical Trials Database record.
15 May 2020 Planned primary completion date changed from 1 Mar 2020 to 1 Aug 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com